Edition:
United Kingdom

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

6.00USD
11 Dec 2017
Change (% chg)

$-0.10 (-1.64%)
Prev Close
$6.10
Open
$6.40
Day's High
$6.50
Day's Low
$5.95
Volume
96,514
Avg. Vol
138,238
52-wk High
$15.45
52-wk Low
$4.05

Latest Key Developments (Source: Significant Developments)

Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ardelyx Inc ::Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China.Ardelyx - under terms of agreement, Ardelyx will receive upfront payment of $12 million, is eligible to receive additional milestones of up to $113 million.Ardelyx Inc - Fosun Pharma will have exclusive rights to market and sell Tenapanor in China.Ardelyx - under terms of agreement, co will receive tiered royalty payments on net sales from Tenapanor ranging from mid-teens to 20 percent.Ardelyx Inc - agreement also provides Fosun Pharma rights to commercialize Tenapanor for other indications for which it is approved in United States.  Full Article

Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Ardelyx Inc :Ardelyx announces updated development path for its cardiorenal pipeline.Ardelyx - second registration study for tenapanor for treatment of hyperphosphatemia will begin enrolling shortly​.Ardelyx - second registration study for tenapanor will begin enrolling shortly after having received feedback from U.S. FDA on trial design.Ardelyx Inc - ‍in addition, co reported clinically meaningful potassium lowering activity from its study for RDX7675 for treatment of hyperkalemia​.Says ‍however, company also observed an unexpected side effect of decreased serum bicarbonate​.Ardelyx Inc - ‍believes the side effect will limit commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675​.Ardelyx inc - ‍ Ardelyx will shift its hyperkalemia efforts to RDX013, its earlier-stage, small-molecule program​.Ardelyx Inc - the change will result in a cash savings of about $40 million to Ardelyx over next two years, extending co's operating runway into 2019​.  Full Article

Ardelyx qtrly ‍net loss per common share $0.44​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Ardelyx Inc ::Ardelyx reports third quarter 2017 operating results and clinical progress.Ardelyx Inc - ‍as of September 30, 2017, Ardelyx had total capital resources including cash, cash equivalents and short-term investments of $129.3 million​.Ardelyx qtrly ‍net loss per common share $0.44​.Ardelyx - phase 3 registration study hit statistical significance for primary endpoint and all secondary endpoints for t3mpo-2.  Full Article

Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ardelyx Inc ::Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing.  Full Article

Ardelyx announces Tenapanor reduces pain caused by IBS-C through inhibition of TRPV-1 signaling
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Ardelyx Inc :Ardelyx announces Tenapanor reduces pain caused by IBS-c through inhibition of TRPV-1 signaling.Ardelyx - ‍data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation​.Ardelyx Inc - ‍moving forward to submit first nda to U.S. FDA for indication in second half of 2018​.  Full Article

Ardelyx says successful trial of hyperphosphatemia treatment
Wednesday, 15 Feb 2017 

Ardelyx Inc : Ardelyx announces successful phase 3 trial of Tenapanor for hyperphosphatemia in patients with end-stage renal disease . Tenapanor was well-tolerated in trial . Ardelyx-Trial results support plans to initiate 2nd phase 3 study of tenapanor for treatment of hyperphosphatemia in esrd patients on dialysis in mid-2017. .Trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint.  Full Article

Ardelyx files for stock shelf of up to $131.2 mln - SEC filing
Thursday, 11 Aug 2016 

Ardelyx Inc : Says files for stock shelf of up to $131.2 million - SEC filing . Says proposed resale or other disposition of up to 12.6 million shares of Ardelyx, Inc common stock Source: (http://bit.ly/2b275ML ) Further company coverage: [ARDX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Ardelyx reports Q2 loss per share $0.83
Monday, 8 Aug 2016 

Ardelyx Inc : Ardelyx reports second quarter 2016 financial results . Q2 earnings per share view $-0.75 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.83 .Licensing revenue for Q2 of 2016 decreased to zero from $17.7 million for Q2 of 2015.  Full Article

Ardelyx says sold $110 mln in equity financing - SEC filing
Monday, 1 Aug 2016 

Ardelyx Inc :Says it has sold $110 million in equity financing - SEC filing.  Full Article

Ardelyx says accelerating plans to commence a time to onset clinical trial in patients with hyperkalemia
Wednesday, 22 Jun 2016 

Ardelyx Inc : Ardelyx reports progress of development programs . Says is accelerating its plans to commence a time to onset clinical trial in patients with hyperkalemia . Fda guided ardelyx to use results of placebo-controlled randomized withdrawal portion of trial as primary endpoint for its clinical trial .Says expects results from ongoing trial to be reported in q1 of 2017, as compared to prior guidance of second half of 2016..  Full Article

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China